SCHEMBL4126301

SCHEMBL4126301

Cc1nn(C(C)(C)C)c(C)c1S(=O)(=O)Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.38
MAPK1 P28482 6/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
GAA P10253 1/20 0.38
HTT P42858 6/20 0.37
NPSR1 Q6W5P4 6/20 0.37
USP2 O75604 3/20 0.37
TSHR P16473 3/20 0.37
MCOLN3 Q8TDD5 2/20 0.37
ALOX15 P16050 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALDH1A1 P00352 3/20 0.34
MAPT P10636 4/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
RAB9A P51151 3/20 0.33
NPC1 O15118 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL347771 0.74 TSHR (0.44) LMNAGAANPSR1TSHRALDH1A1
SCHEMBL15550394 0.69 SMN1; SMN2 (0.44) LMNAHTTALOX15SMN1; SMN2ALDH1A1
SCHEMBL13148356 0.69 GLS (0.41) MAPK1SMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL2454466 0.68 MAPT (0.40) LMNAMAPK1CYP3A4CYP2C9CYP2C19
SCHEMBL2005829 0.68 FPR2 (0.43) TDP1
SCHEMBL13148355 0.68 HPGD (0.37) MAPK1TSHRSMN1; SMN2ALDH1A1MAPT
SCHEMBL15716050 0.66 HPGD (0.36) SMN1; SMN2
SCHEMBL3007153 0.66 KDM4E (0.71) LMNAMAPK1HTTNPSR1ALOX15
SCHEMBL21719161 0.65 NPC1 (0.35) MAPK1GAASMN1; SMN2ALDH1A1MAPT
SCHEMBL4106131 0.65 NR3C1 (0.39) MAPK1CYP3A4CYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090124607-A1 Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-05-14 US disclosed
EP-1940800-A1 NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES Astra Zeneca AB (SE) 2008-07-09 EP disclosed
WO-2007046747-A1 NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES ASTRAZENECA AB (SE) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124607-A1 Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases NR3C1, NR3C2, MC2R LMNA 4705/4885MAPK1 1295/4885CYP3A4 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.